The mission of EpiPredict is to train a multidisciplinary cohort of young researchers in a new approach to fully exploit the epigenetics of complex diseases. The 12 early-stage researchers (ESRs) will focus on a narrowly defined case, Tamoxifen-induced resistance in Estrogen Receptor positive (ER+) breast cancer, considering five interacting resistance pathways. Read more...
Please visit our news page for the latest announcements and press or our Facebook or Twitter pages!
EpiPredict's Prof. Dr Marianne Rots (UMCG , NL) was interviewed for the feature story of August 2017 in Nature Medicine.
Two EpiPredict early stage researchers on epigenetics. Stefania Astrologo (ESR1, UvA, NL) and Désirée Goubert (ESR8, UMCG, NL) wrote together with EpiPredict outreach partner Biotecture a blog in the online publishing platform Medium.
An international team of researchers, including EpiPredict researchers, discovered a mechanism that makes a common type of breast cancer cells resistant to a specific form of hormone treatment. This was published online in Nature Genetics, 23 Jan 2017.
Will Beckman (ESR3, UvA) together with EpiPredict Partner Organisation Biotecture wrote a blog in Medium, ‘From Lab bench to Bed, How understanding epigenetics could benefit breast cancer patients’.
Systems epigenetics: towards precision cancer medicine conference
Amsterdam, NL, 27-30 November 2018
Second EpiPredict Science Café
Imperial College London, UK, Thursday 14, December, 2017
Specific patient representatives will be invited for this meeting between the Early Stage Researchers and patients.